A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of V181 Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults 59 Years of Age or Older

Project: Research project

Project Details

StatusActive
Effective start/end date10/17/23 → 10/16/28

Funding

  • Merck Sharp and Cohme Corporation: $8,000.00